Gravitate Health FHIR Implementation Guide, published by Gravitate Health Project. This guide is not an authorized publication; it is the continuous build for version 0.1.0 built by the FHIR (HL7® FHIR® Standard) CI Build. This version is based on the current content of https://github.com/joofio/test-epi-composition/ and changes regularly. See the Directory of published versions
Full name:
Authorised dose form:
Legal status of supply:
Domain:
Resource status:
Product classification:
Document Details
Generated Narrative: Bundle TEST PURPOSES ONLY - tresiba
Language: en
Profile: Bundle - ePI
Final Document at 2022-02-16 13:28:17+0000 by Organization ACME industry for Bundle: identifier = http://ema.europa.eu/identifier#None; type = document; timestamp = 2023-06-27 10:09:22+0000
Document Subject
Generated Narrative: MedicinalProductDefinition mpfab5fa92013ddb0c611232569286ddbb
identifier: http://ema.europa.eu/identifier
/EU/1/12/807/001
type: Medicinal Product
domain: Human use
status: active
legalStatusOfSupply: Medicinal product subject to medical prescription
name
productName: Tresiba 100 units/mL solution for injection in pre-filled pen
type: Full name
part
part: nan
type: Invented name part
part
part: nan
type: Scientific name part
part
part: nan
type: Strength part
part
part: nan
type: Pharmaceutical dose form part
Usages
Country Jurisdiction Language EU EU en
Document Content
Generated Narrative: Composition composition-en-fab5fa92013ddb0c611232569286ddbb
Language: en
Profile: Composition (ePI)
identifier: http://ema.europa.eu/identifier
/EU/1/12/807/001
status: Final
type: Package Leaflet
category: Raw
date: 2022-02-16 13:28:17+0000
author: Organization ACME industry
title: TEST PURPOSES ONLY - tresiba
Mode | Time |
Official | 2022-02-16 13:28:17+0000 |
What is in this leaflet
Tresiba is a long-acting basal insulin called insulin degludec. It is used to treat diabetes mellitus in adults, adolescents and children aged 1 year and above. Tresiba helps your body reduce your blood sugar level. It is used for once-daily dosing. On occasions when you cannot follow your regular dosing schedule, you can change the time of dosing because Tresiba has a long blood sugar-lowering effect (see section 3 for Flexibility in dosing time ). Tresiba can be used with meal-related rapid-acting insulin products. In type 2 diabetes mellitus, Tresiba may be used in combination with tablets for diabetes or with injectable antidiabetic medicines, other than insulin.
In type 1 diabetes mellitus, Tresiba must always be used in combination with meal-related rapid-acting insulin medicines.
Do not use Tresiba
Warnings and precautions Talk to your doctor, pharmacist or nurse before using Tresiba. Be especially aware of the following:
Children and adolescents Tresiba can be used in adolescents and children aged 1 year and above. There is no experience with the use of Tresiba in children below the age of 1 year.
Other medicines and Tresiba Tell your doctor, pharmacist or nurse if you are taking, have recently taken or might take any other medicines. Some medicines affect your blood sugar level, this may mean your insulin dose has to be changed.
Listed below are the most common medicines which may affect your insulin treatment.
Your blood sugar level may fall (hypoglycaemia) if you take:
Your blood sugar level may rise (hyperglycaemia) if you take:
Octreotide and lanreotide: used to treat a rare condition involving too much growth hormone (acromegaly). They may increase or decrease your blood sugar level.
Pioglitazone: oral antidiabetic medicine used to treat type 2 diabetes mellitus. Some patients with long-standing type 2 diabetes mellitus and heart disease or previous stroke who were treated with pioglitazone and insulin experienced the development of heart failure. Inform your doctor immediately if you experience signs of heart failure such as unusual shortness of breath, rapid increase in weight or localised swelling (oedema).
If any of the above applies to you (or you are not sure), talk to your doctor, pharmacist or nurse.
Tresiba with alcohol If you drink alcohol, your need for insulin may change. Your blood sugar level may either rise or fall. You should therefore monitor your blood sugar level more often than usual.
Pregnancy and breast-feeding If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor or pharmacist for advice before taking this medicine. Your insulin dose may need to be changed during pregnancy and after delivery. Careful control of your diabetes is needed in pregnancy. Avoiding too low blood sugar (hypoglycaemia) is particularly important for the health of your baby.
Driving and using machines Having too low or too high blood sugar can affect your ability to drive or use any tools or machines. If your blood sugar is too low or too high, your ability to concentrate or react might be affected. This could be dangerous to yourself or others. Ask your doctor whether you can drive if:
Important information about some of the ingredients of Tresiba This medicine contains less than 1 mmol sodium (23 mg) per dose. This means that the medicine is essentially sodium-free .
Always use this medicine exactly as your doctor has told you. Check with your doctor, pharmacist or nurse if you are not sure.
If you are blind or have poor eyesight and cannot read the dose counter on the pen, do not use this pen without help. Get help from a person with good eyesight who is trained to use the FlexTouch pre-filled pen.
Tresiba in a pre-filled pen is available in two strengths. Tresiba 100 units/mL or Tresiba 200 units/mL is clearly marked on the pen label and packaging. In addition, Tresiba 100 units/mL packaging and label are light green, and Tresiba 200 units/mL packaging and label are dark green with striping with a red box highlighting the formulation strength.
For both strengths, the needed dose is dialled in units. The dose steps, however, differ between the two strengths of Tresiba.
The pre-filled pen 100 units/mL can provide a dose of 1 80 units in one injection in steps of 1 unit. The dose counter of the pre-filled pen shows the number of units of insulin to be injected. Do not make any dose re-calculation.
Your doctor will decide together with you:
Flexibility in dosing time
Based on your blood sugar level, your doctor may change your dose.
When using other medicines, ask your doctor if your treatment needs to be adjusted.
Use in elderly ( 65 years old) Tresiba can be used in elderly, but if you are elderly, you may need to check your blood sugar level more often. Talk to your doctor about changes in your dose.
If you have kidney or liver problems If you have kidney or liver problems, you may need to check your blood sugar level more often. Talk to your doctor about changes in your dose.
Injecting your medicine
Before you use Tresiba for the first time, your doctor or nurse will show you how to use the pre-filled pen.
Do not use Tresiba
How to inject
Detailed instructions for use are provided on the other side of this leaflet.
If you use more Tresiba than you should If you use too much insulin, your blood sugar may get too low (hypoglycaemia), see advice in section 4 Too low blood sugar .
If you forget to use Tresiba If you forget a dose, inject the missed dose when discovering the mistake, ensuring a minimum of 8 hours between doses. If you discover that you missed your previous dose when it is time to take your next regular scheduled dose, do not inject a double dose, but resume your once-daily dosing schedule.
If you stop using Tresiba Do not stop using your insulin without talking to your doctor. If you stop using your insulin, this could lead to a very high blood sugar level and ketoacidosis (a condition with too much acid in the blood), see advice in section 4 Too high blood sugar .
Like all medicines, this medicine can cause side effects, although not everybody gets them.
Hypoglycaemia (too low blood sugar) may occur very commonly with insulin treatment (may affect more than 1 in 10 people). It can be very serious. If your blood sugar level falls too much, you may become unconscious. Serious hypoglycaemia may cause brain damage and may be life-threatening. If you have symptoms of low blood sugar, take actions to increase your blood sugar level immediately. See advice in Too low blood sugar below.
If you have a serious allergic reaction (seen rarely) to the insulin or any of the ingredients in Tresiba, stop using this medicine and see a doctor straight away. The signs of a serious allergic reaction are:
Skin changes at the injection site: If you inject insulin at the same place, the fatty tissue may shrink (lipoatrophy) or thicken (lipohypertrophy) (may affect up to 1 in 100 people). Lumps under the skin may also be caused by build-up of a protein called amyloid (cutaneous amyloidosis; how often this occurs is not known). The insulin may not work very well if you inject into a lumpy, shrunken or thickened area. Change the injection site with each injection to help prevent these skin changes.
Other side effects include:
Common (may affect up to 1 in 10 people) Local reactions: Local reactions at the place you inject yourself may occur. The signs may include: pain, redness, hives, swelling and itching. The reactions usually disappear after a few days. See your doctor if they do not disappear after a few weeks. Stop using Tresiba and see a doctor straight away if the reactions become serious. For more information, see serious allergic reaction above.
Uncommon (may affect up to 1 in 100 people) Swelling around your joints: When you first start using your medicine, your body may keep more water than it should. This causes swelling around your ankles and other joints. This is usually only short-lasting.
Rare (may affect up to 1 in 1,000 people) This medicine can cause allergic reactions such as hives, swelling of the tongue and lips, diarrhoea, nausea, tiredness and itching.
General effects from diabetes treatment
Too low blood sugar may happen if you: drink alcohol; use too much insulin; exercise more than usual; eat too little or miss a meal.
Warning signs of too low blood sugar these may come on suddenly: Headache; slurred speech; fast heartbeat; cold sweat, cool pale skin; feeling sick, feeling very hungry; tremor or feeling nervous or worried; feeling unusually tired, weak and sleepy; feeling confused, difficulty in concentrating; short-lasting changes in your sight.
What to do if you get too low blood sugar
What others need to do if you pass out
Tell everyone you spend time with that you have diabetes. Tell them what could happen if your blood sugar gets too low, including the risk of passing out.
Let them know that if you pass out, they must:
You may recover more quickly from passing out with an injection of glucagon. This can only be given by someone who knows how to use it.
Talk to your doctor if:
your blood sugar got so low that you passed out
you have used an injection of glucagon
you have had too low blood sugar a few times recently. This is because the dosing or timing of your insulin injections, food or exercise may need to be changed.
Too high blood sugar (hyperglycaemia)
Too high blood sugar may happen if you: eat more or exercise less than usual; drink alcohol; get an infection or a fever; have not used enough insulin; keep using less insulin than you need; forget to use your insulin or stop using insulin without talking to your doctor.
Warning signs of too high blood sugar these normally appear gradually: Flushed, dry skin; feeling sleepy or tired; dry mouth, fruity (acetone) breath; urinating more often, feeling thirsty; losing your appetite, feeling or being sick (nausea or vomiting). These may be signs of a very serious condition called ketoacidosis. This is a build-up of acid in the blood because the body is breaking down fat instead of sugar. If not treated, this could lead to diabetic coma and eventually death.
What to do if you get too high blood sugar
Reporting of side effects If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via the national reporting system listed in Appendix V. By reporting side effects you can help provide more information on the safety of this medicine.
Keep this medicine out of the sight and reach of children. Do not use this medicine after the expiry date which is stated on the pen label and carton, after EXP . The expiry date refers to the last day of that month.
Before first use Store in a refrigerator (2 C to 8 C). Do not freeze. Keep away from the freezing element. Keep the cap on the pen in order to protect it from light.
After first opening or if carried as a spare You can carry your Tresiba pre-filled pen (FlexTouch) with you and keep it at room temperature (not above 30 C) or in a refrigerator (2 C to 8 C) for up to 8 weeks.
Always keep the cap on the pen when you are not using it in order to protect it from light.
Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.
What Tresiba contains
The active substance is insulin degludec. Each mL of solution contains 100 units of insulin degludec. Each pre-filled pen contains 300 units of insulin degludec in 3 mL solution.
The other ingredients are glycerol, metacresol, phenol, zinc acetate, hydrochloric acid and sodium hydroxide (for pH adjustment) and water for injections (see section 2).
What Tresiba looks like and contents of the pack Tresiba is presented as a clear and colourless solution for injection in a pre-filled pen (300 units per 3 mL).
Pack sizes of 1 (with or without needles), 5 (without needles) and multipack of 10 (2 x 5) (without needles) pre-filled pens of 3 mL. Not all pack sizes may be marketed.
Marketing Authorisation Holder
Novo Nordisk A/S Novo All
DK-2880 Bagsv rd, Denmark
Manufacturer
The manufacturer can be identified by the batch number printed on the slip of the carton and on the label:
If the second and third characters are P5, ZF or FG, the manufacturer is Novo Nordisk A/S, Novo All , DK-2880 Bagsv rd, Denmark.
If the second and third characters are T6, the manufacturer is Novo Nordisk Production SAS, Avenue d Orl ans, 28000 Chartres, France.
This leaflet was last revised in
Detailed information on this medicine is available on the European Medicines Agency web site:
Entry 1 - fullUrl = Composition/composition-en-fab5fa92013ddb0c611232569286ddbb
Resource Composition:
Generated Narrative: Composition composition-en-fab5fa92013ddb0c611232569286ddbb
Language: en
Profile: Composition (ePI)
identifier:
http://ema.europa.eu/identifier
/EU/1/12/807/001status: Final
type: Package Leaflet
category: Raw
date: 2022-02-16 13:28:17+0000
author: Organization ACME industry
title: TEST PURPOSES ONLY - tresiba
Attesters
Mode Time Official 2022-02-16 13:28:17+0000
Entry 2 - fullUrl = MedicinalProductDefinition/mpfab5fa92013ddb0c611232569286ddbb
Resource MedicinalProductDefinition:
Generated Narrative: MedicinalProductDefinition mpfab5fa92013ddb0c611232569286ddbb
identifier:
http://ema.europa.eu/identifier
/EU/1/12/807/001type: Medicinal Product
domain: Human use
status: active
legalStatusOfSupply: Medicinal product subject to medical prescription
name
productName: Tresiba 100 units/mL solution for injection in pre-filled pen
type: Full name
part
part: nan
type: Invented name part
part
part: nan
type: Scientific name part
part
part: nan
type: Strength part
part
part: nan
type: Pharmaceutical dose form part
Usages
Country Jurisdiction Language EU EU en